Beta Carotene

Beta Carotene

SCHEMBL5316237

CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C2=C(C)CCCC2(C)C)C(C)(C)CCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 1.00
PTGS1 P23219 4/20 1.00
LMNA P02545 3/20 1.00
DRD3 P35462 2/20 1.00
SLCO1B3 Q9NPD5 2/20 1.00
SLCO1B1 Q9Y6L6 2/20 1.00
APP P05067 4/20 0.85
SNCA P37840 4/20 0.85
CYP3A4 P08684 7/20 0.84
ALOX15 P16050 5/20 0.84
TDP1 Q9NUW8 3/20 0.84
TSHR P16473 2/20 0.84
TP53 P04637 2/20 0.84
NR2E1 Q9Y466 1/20 0.84
MAPT P10636 9/20 0.80
RXRA P19793 5/20 0.80
RARA P10276 4/20 0.80
RARB P10826 4/20 0.80
RARG P13631 4/20 0.80
MAPK1 P28482 4/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Beta Carotene SCHEMBL26362434 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL29636150 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL29445419 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL2300399 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL15066330 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL6151 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL29360574 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL135090 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL20996197 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1LMNADRD3SLCO1B3
Beta Carotene SCHEMBL16114545 0.98 ALDH1A1 (0.97) ALDH1A1PTGS1LMNADRD3SLCO1B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000639-A1 SYNERGY FOR INCREASING ENERGY EXPENDITURE AND INSULIN SENSITIVITY THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2026-01-01 US disclosed
US-12389932-B2 Microalgal food compositions CORBION BIOTECH, INC. 2025-08-19 US disclosed
US-12059006-B2 Microalgal flour CORBION BIOTECH, INC. 2024-08-13 US disclosed
US-20240226255-A9 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-07-11 US disclosed
US-20240131130-A1 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS UNIV CALIFORNIA (US) 2024-04-25 US disclosed
CN-117643738-A High-proportion cis-carotene extract and its preparing process 内蒙古兰太药业有限责任公司 2024-03-05 CN disclosed
US-20230390240-A1 METHODS OF TREATMENT UNIV LOUISIANA STATE (US) 2023-12-07 US disclosed
WO-2023052387-A1 METHOD OF EXTRACTION OF CAROTENOIDS FROM DUNALIELLA, COMPOSITIONS AND USE FOR TREATING CAROTENOID AND PRO-VITAMIN A DEFICIENCIES GIVAUDAN SA (CH) 2023-04-06 WO disclosed
EP-3622828-B1 NOVEL MICROALGAL FOOD COMPOSITIONS CORBION BIOTECH INC (US) 2022-11-16 EP disclosed
EP-2339925-B1 FOOD COMPOSITIONS OF MICROALGAL BIOMASS CORBION BIOTECH INC (US) 2022-09-21 EP disclosed
US-20220291237-A1 Gene Expression Inflammatory Age and Its Uses Edifice Health, Inc. (US) 2022-09-15 US disclosed
WO-2022090547-A1 PRODUCTION OF CAROTENOIDS BY FERMENTATION DSM IP ASSETS B.V. (NL) 2022-05-05 WO disclosed
WO-2022087437-A1 METHODS OF TREATMENT BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2022-04-28 WO disclosed
EP-1848424-A2 PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL MYLAN LABORATORIES, INC (US) 2007-10-31 EP disclosed
WO-2007062415-A1 CORPOREAL DELIVERY OF CAROTENOIDS GRINRX (US) 2007-05-31 WO disclosed
WO-2006083779-A2 PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL MYLAN LABORATORIES, INC. (US) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000639-A1 SYNERGY FOR INCREASING ENERGY EXPENDITURE AND INSULIN SENSITIVITY GPR119, PC, SLC2A9 ALDH1A1 2153/4885PTGS1 3618/4885LMNA 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.